Premium
Thiothixene, thioridazine, and placebo in male chronic schizophrenic patients
Author(s) -
Wolpert Arthur,
Sheppard Charles,
Merlis Sidney
Publication year - 1968
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196894456
Subject(s) - thioridazine , placebo , medicine , incidence (geometry) , population , chlorpromazine , alternative medicine , pathology , physics , environmental health , optics
The population of a male chronic schizophrenic ward was selected for treatment with thiothixene (Navane) (35 subjects), thioridazine (Mellaril) (29 subjects), and/or placebo (28 subjects). Medication was administered for seven months. During this period, the maximum daily dosage reached was 55 mg. of thiothixene and 1,100 mg. of thioridazine. Because of the high incidence of untoward effects and the absence of a marked therapeutic effect, daily dosage was titrated to an average of 10 mg. of thiothixene and 200 mg. of thioridazine during the last four months of treatment. On the basis of the fivefold criteria for determining efficacy (statistical comparisons of the behavioral ratings, psychological test data, the number of treatment failures in each medication group, and the incidence of side effects and patient status at the close of the study), thioridazine appeared slightly more effective in the treatment of schizophrenic symptomatology in this series of patients.